Avenue Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 7 - Stockholder's Equity (Details Textual)

Note 7 - Stockholder's Equity (Details Textual) $ / shares in Units, $ in Thousands		12 Months Ended
	Jun. 24, 2024 shares	Dec. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	May 31, 2024 USD ($)	May 01, 2024 USD ($)	Jan. 31, 2024 USD ($)	Jan. 09, 2024 shares	Dec. 31, 2023 shares	Jan. 30, 2023 shares	Sep. 22, 2022	Dec. 31, 2021 shares	Sep. 13, 2019 $ / shares	Sep. 13, 2016 shares
Preferred Stock, Shares Authorized (in shares)		2,000,000	2,000,000										2,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares		$ 0.0001	$ 0.0001
Common Stock, Shares Authorized (in shares)		200,000,000	200,000,000				200,000,000	75,000,000
Common Stock, Shares, Outstanding (in shares)		3,183,558	2,108,670
Share-Based Payment Arrangement, Expense \| $		$ 665	$ 1,236
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		9 months 18 days
Class of Warrant or Right, Expired during Period (in shares)		703,459
Series B Warrants Associated with November 2023 Public Offering [Member]
Class of Warrant or Right, Expired during Period (in shares)		13,779
Series D Warrants [Member]
Class of Warrant or Right, Expired during Period (in shares)		689,680
January 2024 Warrant Inducement [Member]
Warrants and Rights Issued Classified as Deemed Dividend \| $						$ 4,300
May 2024 Warrant Inducement [Member]
Warrants and Rights Issued Classified as Deemed Dividend \| $				$ 4,500	$ 4,500
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Expense \| $		$ 200	400
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount \| $		$ 100
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years
Share-Based Payment Arrangement, Expense \| $		$ 500	$ 800
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount \| $		$ 100
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		9 months 18 days
Two Thousand Fifteen Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	5,070,223										3,556
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		4,575,906
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
Two Thousand Fifteen Incentive Plan [Member] \| Maximum [Member] \| Incentive Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	5,000,000
Two Thousand Fifteen Incentive Plan [Member] \| Maximum [Member] \| Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)									70,223
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	500,000
Preferred Class A [Member]
Preferred Stock, Shares Authorized (in shares)													250,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares												$ 0.0001
Preferred Stock, Convertible, Conversion Ratio										1,125